Award type :
Product Development Award
Product Development Award
Product type :
Diagnostics
Diagnostics
Award year :
2021
2021
Project start date :
05 / 31 / 2021
05 / 31 / 2021
Project end date :
01 / 31 / 2023
01 / 31 / 2023
Project duration (months) :
20
20
Development stage :
Late Validation
Late Validation
Target disease :
Severe fever with thrombocytopenia syndrome (SFTS)
Severe fever with thrombocytopenia syndrome (SFTS)
Region served :
China, Republic of Korea, Japan, Taiwan, Vietnam,
China, Republic of Korea, Japan, Taiwan, Vietnam,
Recipient organization / Country of funding recipient organization :
Boreda Biotech / Republic of Korea
Boreda Biotech / Republic of Korea
Collaborator(s) / Country :
-
-
Funding amount(KRW) :
500,000,000
500,000,000
SFTS is an emerging tick-borne viral disease, with approximately 14,000 cases reported across Asia as of 2018. Despite its emerging status, no treatments, vaccines, or testing is available for acute infection of this virus. The development of SFTS antigen detection rapid diagnostic test (RDT) with higher sensitivity and specificity will allow for its wider use and overcome the limitations of the current laboratory-based PCR testing. The availability of such antigen detecting point-of-care tests are crucial in managing the spread of emerging infectious diseases.